EUVIMEDEUVIMED entdecken
Crossref

DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples

Chen Ji, Yongming Han, Junru Li, Jie Wei, Wenzhi Yang, Xiaohan Cai, Siqi Tian, Congshuo Chen, Yuzheng Wang, Peipei Zhao, Shan Cao, Wenhao Zhang und 5 weitere

Small Methods · 2025-07 · 9 (7)

DOI: 10.1002/smtd.202402130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small Methods, online erschienen am 27.03.2025. Verfasst von Chen Ji und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Sh…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Biosensing Techniques, DNA, Lipocalin-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Natural Science Foundation, Medical-Engineering Joint Funds from the Shanghai Jiao Tong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein markers secreted by various human cells provide crucial insights for the early diagnosis and prognostic assessment of clinical diseases. However, restricted by efficient protein marker signal amplification in real clinical samples with complex compositions, accurate, sensitive, and rapid detection of protein markers remains largely challenging. Herein, a DNA nanoflower (DNF)‐powered CRISPR/Cas12a biosensing platform (DNF‐CRISPR) is presented that employs the DNF in upstream to amplify input signals for protein markers, while utilizing the CRISPR system in downstream to amplify output signals by trans cleavage. This upstream and downstream cascade amplification sensing platform exhibits high sensitivity (500 fg mL −1 ), rapid (≤2 h), and a broad dynamic range (2.5 pg mL −1 to 25 ng mL −1 ). As a proof of concept, DNF‐CRISPR biosensing platform enables the quantitative detection of neutrophil gelatinase‐associated lipocalin (NGAL) biomarkers in blood and urine samples from kidney injury patients with 91% accuracy. This study provides a powerful and versatile approach for the accurate diagnosis of protein markers in clinical settings, facilitating the application of CRISPR/Cas12a‐based sensing platforms for non‐nucleic acid markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsBiosensing TechniquesDNALipocalin-2HumansBiomarkersBacterial ProteinsEndodeoxyribonucleasesCRISPR-Associated Proteins

Stichwörter der Autor:innen

CRISPR/Cas12aDNA nanoflowerdetection platformkidney injuryprotein biomarker

Substanzen

DNALipocalin-2BiomarkersLCN2 protein, humanCas12a proteinBacterial ProteinsEndodeoxyribonucleasesCRISPR-Associated Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
  • Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital, Renji Hospital Jiading Branch, Shanghai, 201800, China.
  • Central Laboratory, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
  • Department of Stomatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China.
  • Department of Urology, Shanghai Pudong New Area People's Hospital, Shanghai, 201299, China.
  • Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

ORCID-Profile: Fengqin Li

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Natural Science Foundation
  • Medical-Engineering Joint Funds from the Shanghai Jiao Tong University
  • Foundation of Shanghai Municipal Health Commission
  • National Key Scientific Infrastructure for Translational Medicine (Shanghai)
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Ji, C., Han, Y., Li, J., Wei, J., Yang, W., Cai, X., Tian, S., Chen, C., Wang, Y., Zhao, P., Cao, S., Zhang, W., Xu, J., Gu, B., Li, F., Liu, P., & Pu, J. (2025). DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples. Small Methods, 9(7). https://doi.org/10.1002/smtd.202402130

Vancouver

Ji C, Han Y, Li J, Wei J, Yang W, Cai X, et al. DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples. Small Methods. 2025;9(7). doi:10.1002/smtd.202402130

BibTeX
@article{Ji2025,
  author = {Ji, Chen and Han, Yongming and Li, Junru and Wei, Jie and Yang, Wenzhi and Cai, Xiaohan and Tian, Siqi and Chen, Congshuo and Wang, Yuzheng and Zhao, Peipei and Cao, Shan and Zhang, Wenhao and Xu, Jinxinyi and Gu, Bin and Li, Fengqin and Liu, Peifeng and Pu, Jun},
  title = {DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples},
  journal = {Small Methods},
  year = {2025},
  volume = {9},
  number = {7},
  doi = {10.1002/smtd.202402130}
}
Kostenlos starten →